PDF
ePub
Citation
Print
Yeol Kim
Abstract
Lung cancer is a leading cause of cancer death worldwide. The effectiveness of lung cancer targeted high-risk population using low dose chest computed tomography has been reported several randomized controlled trials. Thus, recently, lung cancer screening to high-risk group is recommended internationally. National Cancer Center reported a lung cancer screening guideline by evidence-based methods in 2015. Korean national lung cancer screening program started from 2019 after evaluation of Korean lung cancer screening demonstration project (K-LUCAS) nationwide. K-LUCAS obtained comparable high early lung cancer detection rate, lower false positive rate and lower complication rate compared with clinical trials conducted in other countries. Also psychological anxiety of screening participants had been low, but willingness of smoking cessation had been increased after screening. This paper will review the evidence of lung cancer screening from clinical trials, also, evaluate the benefits and harms of screening based on K-LUCAS.
Figures and Tables
Table 1
Summary of important outcomes of studies on population-based lung cancer screening
Abbreviation: DANTE, Detection and Screening of Early Lung Cancer by Novel Imaging Technology and Molecular Essays Trial; DLST, Danish Lung Cancer Screening Trial; LUSI, German Lung Cancer Screening Intervention Trial; MILD, Multi-centric Italian Lung Detection; NA, non applicable; NELSON, Dutch-Belgian Randomized Lung Cancer Screening Trial; NLST, National Lung Screening Trial; UKLS, United Kingdom Lung Screen.
References
1. World Health Organization (WHO). Cancer Fact [Internet]. Geneva: WHO;2018. Accessed Nov 1, 2019. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer.
2. National Cancer Information Center. Cancer statistics [Internet]. Goyang: National Cancer Information Center;2016. Accessed Nov 1, 2019. Available from: https://www.cancer.go.kr/lay1/S1T639C640/contents.do.
3. National Lung Screening Trial Research Team. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. New Engl J Med. 2011; 365(5):395–409.
4. Jang SH, Sheen S, Kim HY, Yim HW, Park BY, Kim JW, et al. The Korean guideline for lung cancer screening. J Korean Med Assoc. 2015; 58(4):291–301.
5. Lee J, Lim J, Kim Y, Kim HY, Goo JM, Lee CT, et al. Development of Protocol for Korean Lung Cancer Screening Project (K-LUCAS) to evaluate effectiveness and feasibility to implement national cancer screening program. Cancer Res Treat. 2019; 51(4):1285–1294.
6. National Cancer Center. Report of Korean lung cancer screening demonstration project results. Goyang: National Cancer Center;2018.
7. Horeweg N, van Rosmalen J, Heuvelmans MA, van der Aalst CM, Vliegenthart R, Scholten ET, et al. Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening. Lancet Oncol. 2014; 15(12):1332–1341.
8. Pinsky PF, Gierada DS, Black W, Munden R, Nath H, Aberle D, et al. Performance of Lung-RADS in the national lung screening trial: a retrospective assessment. Ann Intern Med. 2015; 162(7):485–491.
9. Pastorino U, Silva M, Sestini S, Sabia F, Boeri M, Cantarutti A, et al. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. Ann Oncol. 2019; 30(7):1162–1169.
10. National Lung Screening Trial Research Team. Lung cancer incidence and mortality with extended follow-up in the national lung screening trial. J Thorac Oncol. 2019; 14(10):1732–1742.
11. Lazris A, Roth AR. Lung cancer screening: pros and cons. Am Fam Physician. 2019; 99(12):740–742.
12. NHS England. Targeted Screening for Lung Cancer with Low Radiation Dose Computed Tomography [Internet]. Redditch: NHS England;2019. Accessed Nov 1, 2019. Available from: https://www.england.nhs.uk/publication/targeted-screening-for-lung-cancer.
XML Download